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COVID-19 Illness and Heart Failure
A Missing Link?
Mandeep R. Mehra, MD, MSC,a Frank Ruschitzka, MDb
I
n the throes of the COVID-19 crisis, a curious
medical fact has emerged. The virus attacks uni-
versally and with high efficiency; however, its
most menacing progression uniquely endangers the
elderly, especially those with cardiovascular illness
such as diabetes mellitus, hypertension, and coronary
heart disease (1). In early reports investigating case
fatality rates, elevated markers of cardiac injury
such as troponin predict a more perilous course and
appear later in the disease course, with some patients
exhibiting extreme elevations in natriuretic peptides
with the cause of death attributed to cardiac failure
and arrest in up to 1 in 4 cases (1). In rare cases, a
fulminant myocarditis-like presentation is observed,
whereas in other post-mortem samples derived in
the setting of death due to pulmonary complications
and cardiac arrest, surprisingly few interstitial mono-
nuclear inflammatory infiltrates are noted without
substantial damage (2,3). As a result of these observa-
tions, a hypothesis is emerging positing the contribu-
tion of underlying structural cardiac disease and
propensity for the emergence of a heart failure
phenotype that ranges from a classic heart failure
with preserved ejection fraction in the earlier stages
of the illness in the context of pulmonary complica-
tions and, later, in the form of acute systolic heart
failure as a response to the cytokine phase of
COVID-19.
One of the most contested issues includes the use
of drugs prescribed for comorbidities, such as hy-
pertension and diabetes mellitus, in patients who go
on to manifest the highest risk for complications with
COVID-19. The question has, therefore, been raised
on whether a blanket avoidance of some drugs, such
as angiotensin-converting enzyme (ACE) inhibitor
(ACEi) and angiotensin receptor blocker (ARB) drug
therapy, should be advisable (4). This is based on the
fact that the SARS-CoV-2 uses the ACE-2 receptor in
the epithelial alveolar lining to establish infection,
and there is ex vivo experimental data suggesting
that drugs such as ACEi of ARBs may induce greater
expression of ACE-2 in tissues other than the pul-
monary vasculature (5). Others have begun to
conjecture about the use of antidiabetic medications
that are secretagogues, which may alter fluid ho-
meostasis. Furthermore, perhaps more appropriately,
some have advocated against the use of non-steroidal
anti-inflammatory drugs (NSAIDs), which should only
be used with caution or ideally, avoided (6). We
believe that recommendations made universally may
be risky if applied to those without the infection or in
young patients who may be less likely to suffer
advanced complications. In reality, interwoven seg-
ments of pathophysiological risk are complicit in
determining the predilection for a more endangered
infection in those with underlying cardiovascular
disease and heart failure.
We have learned that during an influenza
outbreak, elderly patients with cardiovascular illness
have higher rates of acute coronary syndromes, car-
diac arrhythmias, and heart failure–related events (7).
The reasons underlying this may relate to increased
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viscosity during febrile illnesses, heightened coagu-
lation systems, proinflammatory effects, or endothe-
lial cell dysfunction (7). Aging-related immunologic
quiescence may also predispose to higher attack rates
in the elderly. Thus, vulnerable populations are more
prone to the early establishment of infection and its
negative consequences. There is no reason to expect
that this would be materially different in the case of
COVID-19. What is somewhat unique in the observa-
tions with COVID-19 relates to the high frequency of
pulmonary complications, noted as bilateral in-
filtrates on computerized scanning, with a high pro-
portion of patients transitioning to hypoxic
respiratory failure. This raises the issue of whether
there is a cardiac contribution to these lung findings
and whether raised filling pressures and a heart fail-
ure phenotype are also in play and are being ignored.
Currently, no studies that examine hemodynamics in
the setting of hypoxic failure in COVID-19 are avail-
able to answer this critical question.
Because respiratory disease is established in the
setting of COVID-19, characteristically, acute respira-
tory distress syndrome is also accompanied by pul-
monary edema, as noted in post-mortem studies (3).
Elderly patients with cardiovascular disease and dia-
betes often have left ventricular hypertrophy, dia-
stolic dysfunction, and even heart failure with
preserved ejection fraction. Thus, if not attended to,
these patients may be prone to higher pulmonary
vascular pressures in the typical critical care scenario
of fluid infusion to maintain blood pressure as well as
administration of parenteral medications. Such in-
dividuals may also receive medications such as
NSAIDs to abrogate constitutional disease symptoms
such as fever and headache. They may also require
insulin or secretagogues when diabetes mellitus is
present, because blood sugars are often elevated in
the stress of acute illness. These drugs notoriously
alter salt and water handling and may worsen respi-
ratory complications, including pulmonary edema
and consequent hypoxia (8,9). If renal failure ensues,
the ability to handle salt and water becomes even
more precarious. Similarly, in situations of pulmo-
nary disease, ACEi are associated with bronchial hy-
perreactivity and can induce a cough in selected
patients, suggesting that their bradykinin up-
regulating effects may influence the respiratory sys-
tem directly (10). Therefore, although there is little
rationale to cease use of ACEi in the asymptomatic
carrier state or very early COVID-19 illness without
lung complications, it may be best to avoid the use of
ACEi and even ARBs if COVID-19 results in pulmonary
inflammation and acute respiratory distress syn-
drome, because it is likely that vasoplegia and renal
dysfunction may be expected to ensue. Ideally, cli-
nicians should exercise caution in the overuse of
intravenous fluids in elderly patients presenting with
COVID-19 illness.
In later stages of COVID-19 illness, a hyper-
inflammatory state is manifest that is akin to a cyto-
kine release syndrome as described in response to
cancer therapy as noted with immune checkpoint in-
hibition and T-cell–engaging therapies such as
chimeric antigen receptor T cells (11). This multi-
systemic syndrome results in elevated cytokines and
dysregulated T cells with lymphopenia (typically an
TABLE 1 Clinical Cardiovascular Concerns in COVID-19 Illness
COVID-19 Infection Concern Interpretation
Asymptomatic or early mild disease with
constitutional symptoms (fever, dry
cough, diarrhea, and headache)
Should background cardiovascular
medications be modified?
 There is no clear evidence that ACEi or ARBs should be
discontinued
 NSAIDs should be used with caution or, ideally, avoided
Moderate disease with pulmonary
complications and shortness of
breath (including hypoxia)
Is there a cardiovascular contribution
to the lung complications?
 Check troponin (evidence of myocardial injury and
prognosis)
 Check natriuretic peptides
 Consider cardiac echocardiography to evaluate for evi-
dence of underlying structural heart disease, high filling
pressures
 Avoid overuse of intravenous fluids, which may worsen
underlying pulmonary edema
Advanced-stage disease with hypoxia,
vasoplegia, and shock
Is there evidence of cardiogenic
contribution to shock, and what
therapy may be potentially curative?
 Check for evidence of hyperinflammation or a cytokine
release storm (elevated troponin, natriuretic peptides,
CRP, and serum ferritin of >1,000 ng/ml (measure IL-6
levels if available)
 If cardiac function is reduced (LVEF <0.50%), consider
supportive care with inotropic therapy but move to
consider anticytokine therapy with drugs such as toci-
lizumab and corticosteroids
Note that therapy in COVID-19 remains experimental.
ACEi ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receptor blockers; CRP ¼ C-reactive protein; IL ¼ interleukin; LVEF ¼ left ventricular ejection fraction.
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early finding), coupled with marked elevations in C-
reactive protein, cytokines such as interleukin (IL) 2
and IL-6, elevated natriuretic peptides (suggesting
cardiac inflammation or dysfunction), and high serum
ferritin. Observations suggest a high frequency of
cardiovascular events, with patients dying from
cardiac arrhythmias and heart failure, once these bio-
markers become established. Pathologically, such
myocardial manifestations are akin to a stress cardio-
myopathy or cytokine-related myocardial dysfunc-
tion, which occurs in the setting of progressive stages
of COVID-19 illness and mimics the syndromes
observed in secondary hemophagocytic lymphohis-
tiocytosis syndrome or macrophage activation syn-
drome characterized by a fulminant and fatal cytokine
release. In this phase, a terminal event could poten-
tially be avoided by the targeted use of anticytokine
measures such as the IL-6 blocker tocilizumab and by
selected use of corticosteroids (12,13). Naturally, these
concepts require validation in clinical trials.
We believe that until universal testing for
COVID-19, clinical trials of antivirals, and a greater
understanding of the late stages of disease become
evident, heart failure specialists must develop a
structured approach to the care of such patients and
be included early in developing algorithms for care of
these patients (Table 1). Destabilization of car-
diometabolic regimens, including cessation of ACE
inhibitors or ARBs in asymptomatic or early-phase
situations, should be avoided, as has been stated by
concerned societies (14). However, once a proin-
flammatory respiratory phase is established with ev-
idence of inflammatory infiltrates and hypoxia, it may
be prudent to avoid their use in that circumstance. In
the elderly, care should be taken to avoid excessive
fluid use and drugs that may alter salt and water
balance, such as NSAIDs, are best avoided. Bio-
markers should be used with distinct attention to the
elderly at highest risk with underlying structural
cardiac disease, and specialists should engage
thoughtfully in defining and managing advanced
heart failure during the hyperinflammation phase of
this illness.
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